ArticleKidney international2012
A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies.
Article in Kidney international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Biomarkers for the detection of renal fibrosis and prediction of renal outcomes: a systematic review.BMC nephrology · 2017Pooled it
- CCR2-overexpressing mesenchymal stromal cell-derived extracellular vesicles loaded with MPA ameliorate lupus nephritis.Journal of nanobiotechnology · 2026Article
- Lupus nephritis.Nature reviews. Disease primers · 2025Review
- Urinary Biomarkers Associated With Pathogenic Pathways Reflecting Histologic Findings in Lupus Nephritis.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Towards clinical translation of urinary vitronectin for non-invasive detection and monitoring of renal fibrosis in kidney transplant patients.Journal of translational medicine · 2024Article
- The association of urinary plasmin level with renal involvement and disease flare among systemic lupus erythematosus patients.Archives of rheumatology · 2022Article
- Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis.Frontiers in immunology · 2022Article
- In-depth review: is hepcidin a marker for the heart and the kidney?Molecular and cellular biochemistry · 2021Review
- Urinary monocyte chemoattractant protein 1 associated with calcium oxalate crystallization in patients with primary hyperoxaluria.BMC nephrology · 2020Article
- Lupus nephritis.Nature reviews. Disease primers · 2020Review
- Use of Cell Cycle Arrest Biomarkers in Conjunction With Classical Markers of Acute Kidney Injury.Critical care medicine · 2019Article
- Proteomic profiling of urine: implications for lupus nephritis.Expert review of proteomics · 2019Review
- Nonproliferative Forms of Lupus Nephritis: An Overview.Rheumatic diseases clinics of North America · 2018Review
- Precision medicine in lupus nephritis: can biomarkers get us there?Translational research : the journal of laboratory and clinical medicine · 2018Review
- Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.Nutrients · 2018Review
- Molecular profile of urine extracellular vesicles from normo-functional kidneys reveal minimal differences between living and deceased donors.BMC nephrology · 2018Article
- Urinary clusterin-a novel urinary biomarker associated with pediatric lupus renal histopathologic features and renal survival.Pediatric nephrology (Berlin, Germany) · 2018Article
- A Predictive Model for Estimation Risk of Proliferative Lupus Nephritis.Chinese medical journal · 2018Article
- Effects of age and gender on reference levels of biomarkers comprising the pediatric Renal Activity Index for Lupus Nephritis (p-RAIL).Pediatric rheumatology online journal · 2017Article
- Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.Nature reviews. Nephrology · 2017Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
The initial treatment of lupus nephritis is usually based on a renal biopsy. Subsequent disease flares, however, are often treated without the benefit of kidney pathology because repeat biopsies are infrequent. A noninvasive, real-time method to assess renal pathology would be useful to adjust treatment and improve outcome. To develop such a method we collected urine samples at or close to the time of 64 biopsies from 61 patients with lupus nephritis to identify potential biomarkers of tubulointerstitial inflammation and correlated these to biopsy parameters scored by a renal pathologist using a semiquantitative scale. Linear discriminant analysis was used to weight variables and derive composite biomarkers that identified the level of tubulointerstitial inflammation based on urine concentrations of monocyte chemotactic protein-1, hepcidin (a marker of active lupus), and liver fatty acid-binding protein. The discriminant function that described the most accurate composite biomarkers included urine monocyte chemotactic protein-1 and serum creatinine as the independent variables. This composite had sensitivity, specificity, positive predictive value, and negative predictive value of 100, 81, 67, and 100%, respectively. Only 14% of the biopsies were misclassified. Thus, specific renal pathologic lesions can be modeled by composite biomarkers to noninvasively follow and adjust the treatment of lupus nephritis reflecting renal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.